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Strengths and limitations of this study
 ► We undertook rapid reviews of prevalence- based 
models and Markov chain models, which have 
been used to give projections of the future preva-
lence of diabetes to examine their data sources and 
assumptions.
 ► We compared projections of the future prevalence of 
diabetes in England from: reports for the prevalence- 
based models; our own Markov chain models (based 
on transition probabilities from our review) and the 
trend in the prevalence of diagnosed diabetes as re-
ported by general practitioners in England (estimat-
ed by ordinary least squares regression analysis).
 ► This study’s limitations are that our reviews were 
rapid and our models are transparent and simple.
ABSTRACT
Objectives To examine validity of prevalence- based 
models giving projections of prevalence of diabetes in 
adults, in England and the UK, and of Markov chain models 
giving estimates of economic impacts of interventions to 
prevent type 2 diabetes (T2D).
Methods Rapid reviews of both types of models. 
Estimation of the future prevalence of T2D in England 
by Markov chain models; and from the trend in the 
prevalence of diabetes, as reported in the Quality and 
Outcomes Framework (QOF), estimated by ordinary least 
squares regression analysis.
Setting Adult population in England and UK.
Main outcome measure Prevalence of T2D in England 
and UK in 2025.
Results The prevalence- based models reviewed use 
sample estimates of past prevalence rates by age and 
sex and projected population changes. Three most recent 
models, including that of Public Health England (PHE), 
neither take account of increases in obesity, nor report 
Confidence Intervals (CIs). The Markov chain models 
reviewed use transition probabilities between states of risk 
and death, estimated from various sources. None of their 
accounts give the full matrix of transition probabilities, 
and only a minority report tests of validation. Their primary 
focus is on estimating the ratio of costs to benefits of 
preventive interventions in those with hyperglycaemia, 
only one reported estimates of those developing T2D in 
the absence of a preventive intervention in the general 
population.
Projections of the prevalence of T2D in England in 2025 
were (in millions) by PHE, 3.95; from the QOF trend, 4.91 
and by two Markov chain models, based on our review, 
5.64 and 9.07.
Conclusions To inform national policies on preventing 
T2D, governments need validated models, designed to 
use available data, which estimate the scale of incidence 
of T2D and survival in the general population, with and 
without preventive interventions.
INTRODUCTION
Rigorous analysis of worldwide trends of 
increases in the preventable onset of type 2 
diabetes (T2D) in adults justifies a call for 
the urgent of implementation of ‘population- 
based interventions that prevent diabetes, 
enhance its early detection and use lifestyle 
and pharmacological interventions to prevent 
or delay its progression to complications’.1 In 
March 2015, National Health Service (NHS) 
England and Public Health England (PHE) 
launched, at scale, the NHS Diabetes Preven-
tion Programme (NDPP), which is a prag-
matic lifestyle intervention that targets adults 
with raised levels of glycated haemoglobin 
(HbA1c) or a fasting plasma glucose (FPG).2 
The NDPP aims ‘to significantly reduce 
the 4 million people in England otherwise 
expected to have T2D by 2025’ based on 
evidence from ‘well- designed randomised 
controlled trials in Finland, the USA, Japan, 
China and India’.3 Many studies have used 
Markov chain models to estimate the impacts 
of such preventive interventions using transi-
tion probabilities between states: ‘normogly-
caemia’ and ‘intermediate hyperglycaemia 
(IH)’ (glucose levels associated with a low 
and high risks of developing T2D), T2D and 
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Figure 1 Review flow chart of epidemiological models. T2D, 
type 2 diabetes.
Figure 2 Review flow charts of Markov chain models. T2D, 
type 2 diabetes.
death. When we tried to use these models,4 we had diffi-
culty in finding details from published models, and the 
models we did develop gave projections of the future 
prevalence of T2D in 2025 in England, in the absence of a 
preventive intervention, which were much higher than 4 
million. That estimate is based on PHE’s prevalence- based 
model5 that gives future projections of the prevalence of 
T2D (at future time t, N(t)) by multiplying projections of 
the country’s population by age and sex (at time t (P(t)) 
by projections of age- specific prevalence of diabetes (at 
time t, D(t)). (N(t)=D(t)* P(t)).) Hence this study, which 
had three aims. First, to compare the model used by PHE 
to project the prevalence of diabetes in England with 
other models applied to England and the UK. Second, to 
identify Markov chain models, we could use to project the 
prevalence of T2D in England. Third, to compare projec-
tions for England of prevalence of diabetes and T2D from 
different models.
Although we have used England for the purpose of 
comparing projections by these different models, our 
study raises general questions about their validity. And 
hence of the evidence available to governments assessing 
the urgency of preventing T2D and choosing between 
different interventions. We consider only adults with 
diabetes. We use ‘diabetes’ to cover all types of diabetes, 
T2D for adults with type 2, ‘true’ prevalence for both 
diagnosed and undiagnosed diabetes and T2D.
METHODS
Rapid reviews
Our comparisons of projections of different models builds 
on two reviews of the literature, which were designed to 
be rapid (not systematic): ‘a type of knowledge synthesis 
in which components of the systematic review process are 
simplified or omitted to produce information in a short 
period of time’.6 We used stringent criteria to identify the 
principal methods of each type of model. These reviews 
were undertaken in March 2018, of articles published at 
any time available on Web of Science and PubMed, which 
together provide a comprehensive coverage of the liter-
ature in the medical and applied health research fields. 
(The search strategy of each review is given in online 
supplementary appendix 1.) Articles included in each 
review were critically appraised and technical specifica-
tions of the models and projections were extracted and 
tabulated. The flow charts in figures 1 and 2 show the 
screening process.
Rapid review 1 aimed to identify primary studies 
published from 2010 of models giving estimates of the 
prevalence of diabetes in adults in England or the UK. We 
examined how the models take account of future changes 
in age- specific prevalence rates and test their validity.
Rapid review 2 aimed to identify primary studies using 
Markov chain models that reported results of interven-
tions to prevent T2D. We reviewed articles using Markov 
models to run economic analyses, utility analyses and 
cost- effectiveness analyses of preventive interventions 
including people diagnosed with IH according to different 
measures: HbA1c, FPG, Impaired Fasting Glucose (IFG) 
and Impaired Glucose Tolerance (IGT). (Definitions are 
given in online supplementary appendix 1.) We reviewed 
the transition probabilities of the different models, and 
whether they were used to estimate the future prevalence 
of T2D without a preventive intervention and tests of vali-
dation. In our discussion, we refer to the systematic review 
by Leal et al7 of models of pre- diabetes populations used 
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Figure 3 Our Markov chain model.
for reported economic outcomes or evaluations, which 
has been recently published.
Our Markov chain models
Our Markov chain models are in Excel (see figure 3) and 
based on a cycle length of 1 year. The transition probabil-
ities between states other than death are based on rapid 
review 2. We estimated English mortality rates using the 
following data sources: age distributions for those with IH 
and diabetes, from combined Health Surveys for England 
(HSE) data (from 2009 to 2013)8; mortality rates by age, 
from the Office of National Statistics (for 2015)9; Hazard 
Ratios (HRs) for those with diabetes (1.32) and T2D 
(1.28) with reference to those without diabetes, from the 
National Diabetes Audit (for 2015–2016).10 We estimated 
mortality rates for those with IH using HRs with reference 
to those with normoglycaemia as estimated (with 95% 
CIs) by a systematic review and meta- analysis11: for IGT 
1.32 (1.23 to 1.40) and for HbA1c 0.97 (0.88 to 1.07). We 
used 1.32 for IGT, but 1 for HbA1c because the estimate 
of 0.97 is not significantly different from 1. We estimated 
mortality rates as follows, for 2015, for the English popu-
lation: for normoglycaemia, 0.6% (compared with 0.9% 
for the general adult population); for IH, 1.9% and 2.3% 
for HbA1c and IGT; and for T2D, 2.3% and 2.2% for 
HbA1c and IGT. The probability of remaining in a state 
was derived as the residual (so all transition probabilities 
from each state sum to one).
In making future projections of the prevalence of T2D 
in England, without a preventive intervention, up to 2035, 
we used PHE estimates for 2015 of those with diabetes12 
and IH,13 and derived the estimate of those with normo-
glycaemia as the residual for the population of England.14 
Given doubts over the reliability of diagnosing IH,15 we 
examined the robustness of our results by using the PHE 
estimate (IH=5.05 million), and the extreme value of 0 
(IH=0). The data sources of our estimates for England, of 
the prevalence of diabetes, IH and normoglycaemia; and 
of mortality rates of those with T2D, IH and normogly-
caemia are given in the text.
Estimating the trend in diagnosed diabetes
We estimated, by OLS regression analysis (using R),16 the 
trend increase in the reported prevalence of diabetes as 
diagnosed by general practitioners in England, in the 
Quality Outcomes Framework (QOF) from 2004–2005 
(2004) to 2017–2018 (2017)).17 We used these estimates 
to give projections of the future prevalence of diagnosed 
diabetes to 2035.
Comparing projections of the prevalence of diabetes
We compared three sets of projections of the prevalence 
of diabetes and T2D in England from:
 ► Different prevalence- based models.
 ► The trend in QOF data.
 ► Our Markov chain models.
The ratios we used for making comparisons across 
different estimates and their sources are as follows:
 ► 75% for the ratio of diagnosed to the true prevalence 
of diabetes.18 19
 ► 90% for the ratio of the prevalence of T2D to 
diabetes.12
Patients and public involvement
Patients and the public were not involved in this research 
study.
RESULTS
Rapid review 1: methods of prevalence-based models
Rapid review 1 of methods of prevalence- based models 
retrieved 633 articles and from their citations we identified 
a further five by snowballing.20 After removing duplicates, 
we screened 597 articles, of which 11 were relevant and fully 
assessed. After reviewing the full articles, five were excluded 
and seven were included in our analysis.5 18 21–25 This review 
identified four different underlying models described in 
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Table 1 Methods of prevalence- based models
Model Method of estimation
Prevalence 
rates used for 
projections
Validation 
against QOF 
data? Model validation? CIs?
Shaw et al21 Logistic regression Age and sex No No No
Guariguata et al26 Logistic regression Age and sex, and 
urban/rural
No No No
Association of 
Public Health 
Observatories18 25
Direct estimation from 
HSE for age, sex and 
IMD. Trend in obesity 
estimated by linear 
regression.
Age and sex, IMD 
(2004), Ethnicity and 
increases in obesity
Yes for 
2008/2009
No Yes
PHE5 Logistic regression Age and sex, 
ethnicity, IMD 2015
Yes for 
2014/2015
Yes: refitting model 
on 70% of data and 
assessing against 
remaining 30%
No
HSE, Health Surveys for England; IMD, Index of Multiple Deprivation; PHE, Public Health England; QOF, Quality and Outcomes Framework.
table 1, which have been used to give five different projec-
tions of the future prevalence of diabetes for England 
and the UK. Two models produce global estimates: Shaw 
et al,21 Guariguata et al,26 which is used by Whiting et al22 
and Guariguata et al23; and two for England only, the PHE 
model,5 and the Association of Public Health Observatories 
(APHO) Diabetes Prevalence Model,18 which is used by 
Hex et al24 and Gatineau et al25
Each prevalence- based model uses: projected popula-
tion changes; and estimates of the true age- specific prev-
alence rates of diabetes, from past annual HSE, which 
are subject to two limitations. First, the small size of the 
sample means that the point estimate for the year of the 
survey is surrounded by large CI estimates. Gatineau et al 
indicate that the HSE survey for 2013 gives point estimate 
of prevalence of 7.3% with CI estimates ranging from 
4.3% to 10.3%.25 The PHE model5 reduces the sampling 
error from HSE by using 3 years of data (2012, 2013 and 
2014). Second, the HSE estimates of prevalence are based 
on those who self- reported a diabetes diagnosis made by 
a doctor (by HbA1c or FPG); and, for those who have not 
been diagnosed and agreed to have a blood test, having 
a HbA1c value of 6.5% or more.5 Hence these estimates 
may be in error because of poor reliability of self- reporting 
or because of actual diagnostic errors. Barry et al (p. 9) 
report that ‘The most commonly used test (HbA1c) is 
neither sensitive nor specific; the fasting glucose test is 
specific but not sensitive’.15 Holman et al (p.6) pointed 
out, however, that ‘Although HbA1c and fasting identify 
different groups of people with undiagnosed diabetes, 
the proportion of people that are identified is similar’.18
Our review aimed to answer two questions about the 
models.
1. How were the models validated? A basic test of the va-
lidity of a forecasting model is to apply this to past data 
to predict a known future for example, does the model 
using HSE data from 2004 predict prevalence as esti-
mated from HSE data in 2014? None of the accounts of 
the models we reviewed reports such a test. The PHE 
model5 was validated by refitting the model on 70% 
of the data (randomly selected) and checking its esti-
mates against the remaining 30% of data.
2. Did the models try to take account of future changes in 
age- specific prevalence rates? Only the APHO model18 
aimed to do this by estimating the net effect of trends 
in: changes in ethnicity; and being overweight and 
obese to create a sex- specific obesity adjustment index. 
They did not, however, give details of how that index 
was modelled. The other three models5 21 26 assumed 
that future age- specific prevalence of diabetes would 
be as estimated from past HSEs.
The prevalence- based models we reviewed are focused 
on estimating geographical variations in the future prev-
alence of diabetes within countries, rather than giving 
sound estimates of future totals.
Rapid review 2: Markov chain models
Rapid review 2 of Markov models identified 304 arti-
cles. An additional one was snowballed. After removing 
duplicates, 222 articles were screened, 20 of them were 
considered relevant and fully assessed. Of these, one was 
excluded because we could not locate it, one did not 
report the results, and one modelled the progression from 
diabetes to its complications only. Table 2 gives details of 
the remaining 17 articles,27–43 ordered in terms of their 
completeness of the information we could find on tran-
sition probabilities. (online supplementary appendix 2 
gives additional information on objectives, model, popu-
lation, outcomes, sensitivity analysis and validation.) Two 
articles did not report the measure of IH used.39 43 Twelve 
reported a model using one risk measure only: nine 
models used IGT,28 29 31–34 37 38 42 two HbA1c36 40 and one 
FPG only.27 Neumann et al reported two models, using 
IFG and IGT28; and Roberts et al,35 three models using 
HbA1c, IGT and IFG. Hence, we reviewed 20 models.
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Table 2 Transition probabilities reported in different models for no preventive intervention (or standard care)
Reference
Measure of 
Intermediate 
Hyperglycaemia (IH) Country
Normoglycaemia 
(NG) to IH IH to NG NG to T2D T2D to NG IH to T2D T2D to IH
Mortality rates 
(relative risk*)
Johansson et 
al,†27
FPG Sweden
Herman et al†38 IGT USA 10.80%49
Palmer et al37 IGT Australia, 
France, 
Germany, 
Switzerland 
and UK
Overall 11% for 
standard care
varies by age 
(10.8% to 11.6%) 
and body mass 
index (9.0% to 
14.3%)50
IH:1.37 (1.05 to 
1.79)
Undiagnosed T2D: 
1.76 (1.17 to 2.66) 
Diagnosed T2D: 
2.26 (1.78 to 2.87)
Zhuo et al†40 HbA1c USA 0.07% to 18.9% 
by HbA1c51
Chen et al39   Taiwan 1.10%52
Zhou et al36 HbA1c USA 0% 0% 0%
Schaufler and 
Wolff41
IGT or IFG Germany male, 2.23% 
female, 1.45%53
Male, 2.51% 
and female, 
1.66%53
Male, 4.79% 
female, 4.23%53
Source given for 
higher mortality 
rates for T2D54
Gillies et al29 IGT UK <65,1.66%
>65, 2.49%55
1.96% based on 
12 studies55–66
Increased risk of 
death with diabetes
(HR) 0.756 
(SE=0.087)67
1% increase in 
HbA1c (HR) 0.104 
(SE=0.03968
Palmer and 
Tucker 30
IGT Australia Reported over 
time for standard 
care69
 ► 10%, year 1
 ► 5.6% year 2
 ► 3.5% years >2
Reported for 
standard care 
4.6%55
0% Reported over 
time for standard 
care
 ► 11%, years 1 
to 350
 ► 5.6%, years 
>350
IH: 1.50 (1.10 to 
2.00)
‘undiagnosed’ T2D: 
1.30 (0.90 to 2.66) 
‘diagnosed’ T2D 
2.30 (1.60 to 3.20)
70
Ikeda et al42 IGT Japan 3.10%71 For standard care 
33.1%72
0% 0% For standard 
care 6.6%72
0% IH: 1.35
T2DM: 3.0373
Smith et al43   USA 4%74 0.40%75 0% 10.80%38 0% IH: 1.776 stable 
T2D: 277 
complicated T2D: 
2.478
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Reference
Measure of 
Intermediate 
Hyperglycaemia (IH) Country
Normoglycaemia 
(NG) to IH IH to NG NG to T2D T2D to NG IH to T2D T2D to IH
Mortality rates 
(relative risk*)
Neumann et al28 IGT Sweden Risk equation 
reported
Risk equation 
reported
0% 0% Risk equation 
reported
Risk 
equation 
reported
No increased risk 
for IH.
T2D mortality not 
reported.
Caro et al31 IGT Canada 16.30% (original 
estimate)
16.20%
(original estimate)
0% 0% 6.30%
(original estimate)
0% IH: 1.45
(original estimate)
Neumann et al32 IGT Germany 16.30%31 16.20%31 0% 0% 6.00%79 0.50% 
(original 
estimate)
Liu et al33 IGT China 1.28%80 11.60%81 0% 0% Initiation ages
25: 6.44%
40: 16.7%
60: 57.8%
82–84
0%
Wong et al34 IGT Hong Kong 16.30%31 16.20%31 0% 0% For usual 
practice, years 
1 to 3, 11%;58 
years >4, 5.6%50
0% IH: 1.50 (1.10 to 
2.00)
T2D: 2.30 (1.60 to 
3.20)30
Roberts et al35 IGT England 6.33%55 8.97%85 0% 0% 4.55%44 0% IH: 1.50
T2D: 1.986
HbA1c England 6.86%55 8.97%85 0% 0% 3.55%44 0% IH: 1.2
T2D: 1.686
IFG (ADA) England 6.86%55 8.97%85 0% 0% 4.74%44 0% IH: 1.2
T2D: 1.6
86
Range (for single 
probabilities)
IGT   1.28%–16.30% 8.97%–16.20%
(and for standard 
care from 3.5% to 
33.1%)
0.00%–2.5% 
(male)
(and 4.6% for 
standard care)
0% 1.96%–10.8%
(and 11% for 
standard care)
0.00%–0.5% IH:1.35 to 1.7
T2D: 1.76 to 3.03
Meta- analyses IGT   4.55%44 IH: 1.32 (1.23 to 
1.40)11
HbA1c   3.55%44 IH: 0.97 (0.88 to 
1.07)11
IFG (ADA)   3.54%44 IH: 1.13,
(1.02 to 1.25)11
0%: not allowed.
*Relative risk over NG specified in,28 29 31 34 42 ranges in parentheses are 95% CIs.
†Models described elsewhere.
FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; IGT, impaired glucose tolerance; T2D, type 2 diabetes.
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Table 3 The trend model from QOF data
Coefficients Value SE T Pr > |T| Lower bound (95%) Upper bound (95%)
Intercept −219 4.375 -50.14 <0.0001 −210 −229
Year 0.110 0.002 50.71 <0.0001 0.105 0.115
Adjusted R squared 0.995
QOF, Quality and Outcomes Framework.
Our objective was to develop a matrix of transition prob-
abilities, with one transition probability only between states, 
and hence designed to use available data for England. 
Table 2 gives the transition probabilities we found and 
shows no article provided the complete matrix of transition 
probabilities. Five only reported the full set between states 
other than death. No article reports transition probabil-
ities from different states to death (ie, mortality rates for 
each state) and, where relative risk of mortality is reported 
for IH and T2D, we could not always find whether this was 
compared with normoglycaemia. Nor could we find how 
these models satisfied the fundamental requirement of a 
Markov chain model that all transition probabilities out of 
a state, estimated from different datasets, (including return 
to that state) sum to one.
Our review aimed to answer three questions about the 
Markov chain models:
1. Do these articles provide evidence of the likely impact 
of national preventive programmes? The primary fo-
cus of the articles we reviewed is on estimating the ra-
tio of costs to benefits of preventive interventions for 
those who are hyperglycaemic (most based on IGT, 
only three for HbA1c, two for IFG and one for FPG). 
None reported the impact of preventive interventions 
on reducing the burden of disease from T2D in the 
general population. Only four articles19 25 31 40 mod-
elled the general population (with normoglycaemia 
and IH).
2. How were the models validated? Whereas most arti-
cles reported outcomes of sensitivity analyses, only five 
reported comparisons of their models’ outputs with 
other empirical data: clinical trials23 32; the population 
with T2D in southern Wisconsin36; the disease progres-
sion of T2D in Germany33; mortality data for England 
and estimates of current prevalence of T2D by age 
group.27 A good empirical test of a model’s validity is 
of its estimates of those developing T2D in the absence 
of a preventive intervention. Only Caro et al31 reported 
this for a general population, but they did not report 
a check against other projections. Of the articles that 
modelled populations with IH, only three reported es-
timates of the percentages developing T2D in the ab-
sence of intervention.15 23 24
3. How do transition probabilities compare? All models, 
except that of Neumann et al,32 allow transitions from 
T2D to T2D or death only. Neumann et al32 allow transi-
tion (at a low probability, 0.5%) from T2D to IH (IGT) 
(because ‘this transition exists but seldom occurs’, p 
4). Only two models allow transition from normogly-
caemia directly to T2D: Schaufler and Wolff41 (IFG or 
IGT—for males, 2.51% and females, 1.66%) and Smith 
et al (measure of IH not specified, 0.40%).43 For the 
transition probabilities reported in table 2, two models 
allow for changes over time23 26; and seven for varia-
tions by age.20–23 25 29 30 Table 2 shows that wide ranges 
of transition probabilities used by the different IGT 
models: from normoglycaemia to IH, 1.28%–16.30%; 
from IH to low, 8.97%–16.20%; normoglycaemia to 
T2D, 0.00%–2.51% (for males); IH to T2D, 1.96%–
10.8%. A meta- analysis recommended a rate of 4.55% 
for the last.44
The relative risks reported for IH for IGT ranged from 
1.35 to 1.7; and T2D from 1.76 to 3.03. Roberts et al35 
report these risks for HbA1c to be 1.2 and 1.6. The es-
timates from the systematic review and meta- analysis11 
for IH were: for IGT 1.32 (1.23–1.40) and for HbA1c 
0.97 (0.88–1.07). One article32 reported a matrix 
in which probabilities of transitions between states 
other than death sum to one, which implies no one 
dies. PHE defines those with IH using either HbA1c 
or IFG.5 The models developed by Roberts et al35 for 
HbA1c and IFG are similar. We used their HbA1c mod-
el to project the prevalence of T2D in England. They 
used the recommended transition probabilities from 
different risk measures of IH to T2D identified by a 
meta- analysis.44 Neumann et al32 and Caro et al31 have 
similar transition probabilities, which are higher than 
those of Roberts et al,35 for IGT from normoglycaemia 
to IH, and IH to T2D: 16.3% and 6.00% compared 
with 6.33% and 4.55%. We used the transition proba-
bilities used by Neumann et al32 because that is more 
recent. Model 1 is based on Roberts et al (HbA1c),35 
which was modified as model 2 to give the projections 
of PHE. To do this, model 2’s transition probability 
from IH to T2D (0.013) is a third of that of model 1 
(0.036), and below the lowest rate of any model we re-
viewed (0.02). (Model 2 has a corresponding increase 
in the transition probability of remaining in IH (0.836 
to 0.878)). Model 3 is based on Neumann et al.32 De-
tails of the models are given in online supplementary 
appendix 1.
Estimating the trend in diagnosed diabetes
Table 3 reports the OLS estimate of the trend in diag-
nosed diabetes from QOF data,17 which gives an annual 
rate of increase of 0.11%.
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Comparing projections of the future prevalence of T2D
Table 4 gives: for the different prevalence- based models 
their defined populations, data sources and projections 
of diabetes true prevalence (in millions); comparable esti-
mates of the true prevalence of diabetes from the QOF 
data and estimated trend (increased by a third) and the 
annual rate of increase in prevalence from the first in the 
series to the last. Table 4 shows that for the three models 
that do not allow for increase in prevalence rates by age 
and sex,21–23 the older the HSE data used, the lower is the 
estimate of the rate of increase in prevalence for England. 
We compare projections of true prevalence of diabetes 
and T2D by different models giving numbers in millions; 
and, in parentheses, CIs (where available).
Global models give three projections of the true prev-
alence for diabetes prevalence in the UK (aged 20–79): 
for 2030, 2.5521 and 3.6522 and 2035, 3.62.23 Each projec-
tion is below the estimate by PHE12 for England for 2015, 
3.81 (based on HSEs for 2012, 2103 and 2014). These 
global models assume low rates of increase in prevalence 
over time and exclude those over 79, who we estimated 
to account for over 25% of the number who would be 
aged 20 to 79 in England and develop diabetes in 2030 
and 2035. The projections by these global models are not 
examined further.
Two models give projections of the true prevalence of 
diabetes for England only (aged over 15): the PHE model12 
for 2030, 4.68 and 2035, 4.94 and APHO for 2030, 4.60 
(3.25 to 6.88).18 The two accounts of the APHO model15 16 
report the same projection for 2030; but one estimated 
the prevalence of diabetes in 2010 (3.10)18 to be higher 
than the other for 2013 (2.17).16 And the increase in 
prevalence to 2030 attributed to increases in obesity was 
estimated to be a half18 and a third.25 Figure 4 compares 
three projections for 2025: PHE,12 4.39; Holman et al 4.19 
(2.93–6.19); and the QOF trend, 5.46 (5.32–5.59), which 
has a narrow CI because this trend has been so stable.
Figure 5 compares projections of the true prevalence 
of T2D in England to 2035, the QOF trend and our three 
Markov chain models. This shows that the projections by 
model 2 replicated the projections by PHE; by model 1 
are above those from PHE and the QOF trend; by model 
3 seem to be implausibly explosive. Figure 5 also shows 
the impact of reducing the estimate of those with IH to 
zero in 2015 on the projections by models 1 and 3. Table 5 
gives projections for 2025, These are: 3.95, by PHE; 4.91 
(4.79–5.03) from the QOF trend; 5.64 by model 1; 3.86 
by model 2 and 9.07 by model 3. Putting the estimate 
of those with IH to zero in 2015 reduces the projections 
by models 1 and 3 to 5.01 and 8.57, which are above the 
projections by PHE and the QOF trend.
DISCUSSION
Akushevich et al45 point out that although the ‘prevalence 
probability of a disease is a fundamental epidemiological 
characteristic’ for which there are various data sources, 
this random variable is the difference between changes 
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Figure 4 Projections of true diabetes prevalence in England: 2005–2035. PHE, Public Health England; QOF, Quality and 
Outcomes Framework.
Figure 5 Projections of the true prevalence of T2D in England: 2015–2035. PHE, Public Health England; QOF, Quality and 
Outcomes Framework; T2D, type 2 diabetes.
over time in disease incidence and patient survival. This 
has a statistical implication that, whatever modelling 
approach is used, we would expect projections of prev-
alence to have large errors of estimation. The policy 
implication, which Akushevich et al emphasise, is that 
the overriding objective ought to be to improve popula-
tion health, rather than reducing the prevalence of T2D: 
because, for example, improving survival of those with 
T2D may increase prevalence (depending on changes 
in incidence). Akushevich et al developed a new meth-
odological approach that partitions trends in observed 
disease prevalence into their two components, and hence 
gives estimates of the direction and strength of the effect 
of each. Their models are estimated from a single data set 
(Medicare data), incorporate changes over time and take 
account of age.
The four prevalence- based models we reviewed10 14 15 17 
use past estimated prevalence rates by age and sex and 
projected changes in populations. They are focused on 
estimating geographical variations in the future prev-
alence of diabetes within countries, rather than giving 
sound estimates of future totals. Only one model aims to 
take account of changes in prevalence rates by age and 
sex over time.15 Of the five projections of diabetes preva-
lence, for England and the UK we reviewed,10–12 14 15 only 
one15 reported CIs.
The Markov chain models of the economic impacts 
of interventions that aim to prevent T2D, which we 
reviewed, aim to capture changes in incidence and 
survival in one model. Their primary focus is on esti-
mating the ratio of costs to benefits of preventive inter-
ventions for those who are hyperglycaemic (mostly based 
on IGT). None reported the impact of preventive inter-
ventions on reducing the burden of disease from T2D in 
the general population. We could not find a complete 
matrix of transition probabilities; nor descriptions of how 
transition probabilities estimated from different datasets 
satisfied the fundamental requirement of a Markov chain 
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Table 5 Projections of the true prevalence of T2D in 
England for 2025
Model
Projections for 2025 (millions)
Statistical
Markov (numbers 
with intermediate 
hyperglycaemia in 
2015)
Point 
estimate 95% CIs 5.05* Zero
PHE 3.95 n.a.
QOF 
trend
4.91 4.79 to 5.03
Model 1† 5.64 5.01
Model 2‡ 3.86
Model 3§ 9.07 8.57
*As estimated by PHE.
†Based on Roberts et al.35
‡Based on Roberts et al,35 but modified to reproduce the PHE 
trend to 2035.
§Based on Neuman et al.32
n.a., not available; PHE, Public Health England; QOF, Quality and 
Outcomes Framework; T2D, type 2 diabetes.
model that all transition probabilities out of a state sum 
to one. The transition probabilities we did find do not 
vary over time. In seven articles these probabilities do vary 
by age.20–23 25 29 30 In their systematic review of models of 
the economic impacts of preventive interventions, Leal 
et al
7 also found the majority of models assumed that 
‘the rate of progression to T2D was constant across the 
entire pre- diabetes population’. They attribute this in 
part to limitations in the available data, but highlight the 
‘stark contrast’ between these simple models and ‘The 
complexity of risk prediction models for diabetes inci-
dence and the variety of covariates used’.46 47 Friedman 
famously48 argued, however, that the relevant question to 
ask about the ‘assumptions’ of economic theory, ‘is not 
whether they are descriptively realistic … but whether the 
theory works, which means that it yields sufficiently accu-
rate predictions’ (p 153).
Three projections of diabetes prevalence (in millions) 
for the UK (aged 20–79) by global models are: for 2030, 
2.5521 22 and 3.65,21 22 and for 2035, 3.62.23 Each is below 
the PHE estimate of 3.81 for 2015 for England only (over 
15).12 This raises questions over the validity of these global 
projections; and their excision of those over 79, who we 
estimated to account for over 25% of the number who 
would be aged 20 to 79 and develop T2D after 2030. We 
report three estimates of diabetes prevalence in England 
for 2025 (with 95% CIs where available): 4.39 by PHE,12 
4.19 (2.93 to 6.19) by the APHO model,18 25 and 5.46 
(5.32 to 5.59) from the QOF trend. We and Leal et al7 
found only minority of articles reported tests of valida-
tion. Such checks are vital for Markov chain models given 
the different data sources used to estimate transition 
probabilities.
Our Markov chain models are based on transition prob-
abilities to states other than death from published models, 
to death from English mortality rates, and of remaining in 
a state as the residual (so all transition probabilities from 
each state sum to one). The projections of prevalence of 
T2D for England for 2025 are: 5.64 by model 1 (based on 
Roberts et al for HbA1c),35 and 9.07 by model 3 (based on 
Neuman et al for IGT).32 To reproduce PHE’s projections 
by model 2, of 3.86, model 1 was modified with a lower 
probability of transition from IH to T2D than any of the 
models we reviewed. These comparisons suggest that the 
PHE projection of T2D prevalence in 2025 of 4 million is 
too low, and a more realistic estimate is about 5 million.
The limitations of our research are our models are 
simple and transparent, and, as we did not undertake 
systematic reviews, we may have omitted relevant articles. 
The systematic review by Leal et al7 reviewed 29 studies, 
which included 12 of the 17 studies of Markov chain 
models that we reviewed. Their principal findings are 
strikingly similar to ours. They recommend the develop-
ment of ‘more comprehensive models that are capable 
of better capturing the continuity in disease progression 
and, also, of incorporating the identification of novel 
biomarkers’. But, they recognise such models require 
more detailed data and only need to be comprehensive 
enough to provide reliable estimates for decision making.
CONCLUSIONS
There are three implications of our reviews of two types of 
models used to project prevalence of T2D. First, current 
prevalence- based models are focused on estimating 
geographical variations in the future prevalence of 
diabetes within countries, rather than giving sound esti-
mates of future totals. They are designed to underestimate 
the scale of increases in the future prevalence of T2D in 
England and the UK, and hence the urgency for govern-
ments to implement preventive interventions. Second, 
the primary focus of the Markov chain models is on esti-
mating the ratio of costs to benefits of preventive interven-
tions for those who are hyperglycaemic (mostly based on 
IGT). We found that no articles gave the complete matrix 
of transition probabilities and a full description of how 
they were derived. Only a minority have been subjected to 
tests of validity. Third, to inform national policies, govern-
ments need estimates of the impacts of preventive inter-
ventions on reducing the burden of disease from T2D 
in the general population. These estimates ought to be 
derived from validated models, designed to use available 
data, that estimate changes over time in the incidence and 
survival of patients with T2D, with and without preventive 
interventions.
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